Increased immunoglobulin binding to cerebral endothelium in patients with antiphospholipid antibodies

David C Hess, James C. Sheppard, Robert J. Adams

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Background and Purpose: There is a strong link between antiphospholipid antibodies and stroke. The mechanism of action of antiphospholipid antibodies is unknown. Most theories of pathogenesis center around platelet or endothelial cell dysfunction. Our aim was to determine if there were immunoglobulins in the sera of patients with antiphospholipid antibodies that bind human brain microvascular endothelial cells. Methods: We studied sera from three groups of subjects: Patients with antiphospholipid antibodies and stroke (group 1), healthy control subjects (group 2), and patients with stroke but without antiphospholipid antibodies (group 3). We isolated human brain microvascular endothelial cells from temporal lobectomy specimens and used a cellular enzyme-linked immunosorbent assay (ELISA) to measure immunoglobulin binding to endothelial cells derived from human brain and from human umbilical vein. We used a chromium release assay to measure cytotoxicity. Results: Patients with antiphospholipid antibodies and stroke had significantly higher immunoglobulin binding to human brain microvascular endothelial cells than subjects in the other groups ([ELISA index+standard deviation], 63+±37 [group 1] versus 7±7 [group 2] versus 7±7 [group 3], P<.001). There was, however, poor correlation between binding to brain endothelial cells and binding to cardiolipin. The binding to brain microvascular cells was not specific to brain endothelium, as similar results were found in an ELISA using human umbilical vein cells. There was no evidence of complement-mediated brain endothelial cell cytotoxicity. Conclusions: Patients with stroke and antiphospholipid antibodies frequently have human brain microvascular endothelial-reactive antibodies in their serum. These antibodies are distinct from those to cardiolipin. We found no evidence that these antibodies are cytotoxic.

Original languageEnglish (US)
Pages (from-to)994-999
Number of pages6
JournalStroke
Volume24
Issue number7
DOIs
StatePublished - Jan 1 1993
Externally publishedYes

Fingerprint

Antiphospholipid Antibodies
Endothelium
Immunoglobulins
Endothelial Cells
Brain
Stroke
Umbilical Veins
Cardiolipins
Enzyme-Linked Immunosorbent Assay
Antibodies
Serum
Chromium
Healthy Volunteers
Blood Platelets
Control Groups

Keywords

  • Anticoagulants, antiphospholipid antibodies
  • Endothelium

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing

Cite this

Increased immunoglobulin binding to cerebral endothelium in patients with antiphospholipid antibodies. / Hess, David C; Sheppard, James C.; Adams, Robert J.

In: Stroke, Vol. 24, No. 7, 01.01.1993, p. 994-999.

Research output: Contribution to journalArticle

Hess, David C ; Sheppard, James C. ; Adams, Robert J. / Increased immunoglobulin binding to cerebral endothelium in patients with antiphospholipid antibodies. In: Stroke. 1993 ; Vol. 24, No. 7. pp. 994-999.
@article{d8e40c24be894cb0988c7cdfeae2c2a4,
title = "Increased immunoglobulin binding to cerebral endothelium in patients with antiphospholipid antibodies",
abstract = "Background and Purpose: There is a strong link between antiphospholipid antibodies and stroke. The mechanism of action of antiphospholipid antibodies is unknown. Most theories of pathogenesis center around platelet or endothelial cell dysfunction. Our aim was to determine if there were immunoglobulins in the sera of patients with antiphospholipid antibodies that bind human brain microvascular endothelial cells. Methods: We studied sera from three groups of subjects: Patients with antiphospholipid antibodies and stroke (group 1), healthy control subjects (group 2), and patients with stroke but without antiphospholipid antibodies (group 3). We isolated human brain microvascular endothelial cells from temporal lobectomy specimens and used a cellular enzyme-linked immunosorbent assay (ELISA) to measure immunoglobulin binding to endothelial cells derived from human brain and from human umbilical vein. We used a chromium release assay to measure cytotoxicity. Results: Patients with antiphospholipid antibodies and stroke had significantly higher immunoglobulin binding to human brain microvascular endothelial cells than subjects in the other groups ([ELISA index+standard deviation], 63+±37 [group 1] versus 7±7 [group 2] versus 7±7 [group 3], P<.001). There was, however, poor correlation between binding to brain endothelial cells and binding to cardiolipin. The binding to brain microvascular cells was not specific to brain endothelium, as similar results were found in an ELISA using human umbilical vein cells. There was no evidence of complement-mediated brain endothelial cell cytotoxicity. Conclusions: Patients with stroke and antiphospholipid antibodies frequently have human brain microvascular endothelial-reactive antibodies in their serum. These antibodies are distinct from those to cardiolipin. We found no evidence that these antibodies are cytotoxic.",
keywords = "Anticoagulants, antiphospholipid antibodies, Endothelium",
author = "Hess, {David C} and Sheppard, {James C.} and Adams, {Robert J.}",
year = "1993",
month = "1",
day = "1",
doi = "10.1161/01.STR.24.7.994",
language = "English (US)",
volume = "24",
pages = "994--999",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Increased immunoglobulin binding to cerebral endothelium in patients with antiphospholipid antibodies

AU - Hess, David C

AU - Sheppard, James C.

AU - Adams, Robert J.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Background and Purpose: There is a strong link between antiphospholipid antibodies and stroke. The mechanism of action of antiphospholipid antibodies is unknown. Most theories of pathogenesis center around platelet or endothelial cell dysfunction. Our aim was to determine if there were immunoglobulins in the sera of patients with antiphospholipid antibodies that bind human brain microvascular endothelial cells. Methods: We studied sera from three groups of subjects: Patients with antiphospholipid antibodies and stroke (group 1), healthy control subjects (group 2), and patients with stroke but without antiphospholipid antibodies (group 3). We isolated human brain microvascular endothelial cells from temporal lobectomy specimens and used a cellular enzyme-linked immunosorbent assay (ELISA) to measure immunoglobulin binding to endothelial cells derived from human brain and from human umbilical vein. We used a chromium release assay to measure cytotoxicity. Results: Patients with antiphospholipid antibodies and stroke had significantly higher immunoglobulin binding to human brain microvascular endothelial cells than subjects in the other groups ([ELISA index+standard deviation], 63+±37 [group 1] versus 7±7 [group 2] versus 7±7 [group 3], P<.001). There was, however, poor correlation between binding to brain endothelial cells and binding to cardiolipin. The binding to brain microvascular cells was not specific to brain endothelium, as similar results were found in an ELISA using human umbilical vein cells. There was no evidence of complement-mediated brain endothelial cell cytotoxicity. Conclusions: Patients with stroke and antiphospholipid antibodies frequently have human brain microvascular endothelial-reactive antibodies in their serum. These antibodies are distinct from those to cardiolipin. We found no evidence that these antibodies are cytotoxic.

AB - Background and Purpose: There is a strong link between antiphospholipid antibodies and stroke. The mechanism of action of antiphospholipid antibodies is unknown. Most theories of pathogenesis center around platelet or endothelial cell dysfunction. Our aim was to determine if there were immunoglobulins in the sera of patients with antiphospholipid antibodies that bind human brain microvascular endothelial cells. Methods: We studied sera from three groups of subjects: Patients with antiphospholipid antibodies and stroke (group 1), healthy control subjects (group 2), and patients with stroke but without antiphospholipid antibodies (group 3). We isolated human brain microvascular endothelial cells from temporal lobectomy specimens and used a cellular enzyme-linked immunosorbent assay (ELISA) to measure immunoglobulin binding to endothelial cells derived from human brain and from human umbilical vein. We used a chromium release assay to measure cytotoxicity. Results: Patients with antiphospholipid antibodies and stroke had significantly higher immunoglobulin binding to human brain microvascular endothelial cells than subjects in the other groups ([ELISA index+standard deviation], 63+±37 [group 1] versus 7±7 [group 2] versus 7±7 [group 3], P<.001). There was, however, poor correlation between binding to brain endothelial cells and binding to cardiolipin. The binding to brain microvascular cells was not specific to brain endothelium, as similar results were found in an ELISA using human umbilical vein cells. There was no evidence of complement-mediated brain endothelial cell cytotoxicity. Conclusions: Patients with stroke and antiphospholipid antibodies frequently have human brain microvascular endothelial-reactive antibodies in their serum. These antibodies are distinct from those to cardiolipin. We found no evidence that these antibodies are cytotoxic.

KW - Anticoagulants, antiphospholipid antibodies

KW - Endothelium

UR - http://www.scopus.com/inward/record.url?scp=0027270527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027270527&partnerID=8YFLogxK

U2 - 10.1161/01.STR.24.7.994

DO - 10.1161/01.STR.24.7.994

M3 - Article

VL - 24

SP - 994

EP - 999

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 7

ER -